Abstract
The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.
Cite
CITATION STYLE
APA
Krystal, J. H., Charney, D. S., & Duman, R. S. (2020, April 2). A New Rapid-Acting Antidepressant. Cell. Cell Press. https://doi.org/10.1016/j.cell.2020.02.033
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free